Who are Two cycles of neoadjuvant chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, TC chemotherapy, Mitomycin-C/ 5-Fluorouracil, chemotherapy of mFOLFOX6 or FOLFIRI, TC, FLOT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/two-cycles-of-neoadjuvant-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Two cycles of neoadjuvant chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Two cycles of neoadjuvant chemotherapy (Two cycles of neoadjuvant chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Two cycles of neoadjuvant chemotherapy (Two cycles of neoadjuvant chemotherapy) — Seoul National University Hospital. Chemotherapy involves the use of drugs to kill rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Two cycles of neoadjuvant chemotherapy TARGET	Two cycles of neoadjuvant chemotherapy	Seoul National University Hospital	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
TC chemotherapy	TC chemotherapy	Agendia	marketed	Chemotherapy combination regimen
Mitomycin-C/ 5-Fluorouracil	Mitomycin-C/ 5-Fluorouracil	Medical University Innsbruck	marketed	Chemotherapy combination (alkylating agent + antimetabolite)
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
TC	TC	AGO Study Group	marketed	Chemotherapy combination regimen
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Two cycles of neoadjuvant chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/two-cycles-of-neoadjuvant-chemotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab